Article
Pharmacokinetics of engineered human monomeric and dimeric CH2 domains.
mAbs - 1 Jan 2000
Gehlsen Kurt, Gong Rui, Bramhill Dave, Wiersma David, Kirkpatrick Shaun, Wang Yangping, Feng Yang, Dimitrov Dimiter S
Abstract excerpt
Therapeutic monoclonal antibodies have several advantages over small molecule drugs and small proteins and peptides, including a long serum half-life. The long serum half-life of IgG is due, in part, to its molecular weight (150kDa) and its ability to bind FcRn. Both the CH2 and CH3 domains of Fc are involved in FcRn binding. Antibody fragments and antibody-like scaffolds have improved penetration into tissues...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.